Skip to content

Page last updated: 19th December 2022

This information is from the Risdiplam Managed Access Agreement (MAA) on the NICE website here.

The MAA for risdiplam outlines the types of data that will be collected from people on the treatment during the managed access period.

This will help answer the uncertainties and knowledge gaps about the treatment that were identified by the original NICE appraisal committee. This data and other information will be reviewed by NICE at the end of the MAA when it considers risdiplam’s clinical and cost effectiveness and whether to recommend that the NHS continues to fund this treatment.

The main sources of information for the risdiplam MAA will be:

  • Clinical Data from patients enrolled in the MAA
  • Clinical Trial Data
  • Patient and Carer Quality of Life Data

This information is gathered in clinic at the treatment centre and shared with either the paediatric SMA REACH UK or the Adult REACH database. You will be asked to sign your consent to storing your data. The ’standard baseline information’ collected includes:

  • Patient & assessment details;
  • SMA Type, including molecular genetic diagnosis;
  • cause of death in event of mortality;
  • nutritional status, including swallowing problems;
  • scoliosis;
  • motor function using SMA validated scales appropriate for the level of function of the patient
  • ventilation / respiratory events;
  • respiratory function tests;
  • treatment use and outcomes; including reasons for treatment discontinuation.

You can read more about what is involved in our page:

Clinical assessment scales and measures – what’s used when

You’ll have an opportunity to fully discuss what information will be collected from you and how it will be kept before you start treatment. You’ll be asked to sign two consent forms:

  • one to receive treatment as part of the MAA, and consent to the agreement terms
  • one to provide your permission to share your data with the database that is collecting and storing data as part of the MAA.

Data will continue to be collected or will continue for people who:

  • meet the stopping criteria and stop treatment
  • choose to stop treatment or choose to use a different treatment for SMA
  • currently receive treatment within the EAMS and are ineligible for treatment under the MAA.

However, data collection for these people is not mandatory.

The Databases are responsible for analysing the data collected within clinical practice and producing the corresponding reports that will be part of the NICE review.

Further data collected from the Clinical Trials will be reviewed. These trials are:


PROMs or Quality of Life (QoL) data can help demonstrate the effect that a treatment has on a patient’s and caregiver’s well-being and their ability to perform everyday tasks. This data collection goes beyond what can be seen with clinical measurements.

Quality of Life (QoL) questionnaires are one way of capturing this information, questions may cover information about:

  • Mobility/walking
  • Ability to undertake daily activities: eating, washing and dressing, self-transfer etc.
  • Limb/joint weakness
  • Pain
  • Fatigue
  • Breathing difficulties, choking or swallowing
  • Speech and other forms of communication
  • Difficulties sleeping at night or daytime sleepiness
  • Weight changes
  • Problems with digestion
  • Psychological and emotional well-being
  • Ability to attend school / college
  • Loss of earnings and productivity (employment)
  • Ability to participate in society
  • Impact on family

The risdiplam MAA states that Roche is responsible for exploring the most appropriate measures and outcomes that capture patient’s and caregivers’ quality of life. Roche has advised that they are collecting PROMS data via the UK SMA Patient Registry.

Find out more and sign up to the UK SMA Patient Registry >

Clinical patient information will be kept centrally by the relevant database and will be heldsecurely in accordance with national regulations. SMA REACH is a network of independent NHS paediatric and adult healthcare professionals who work together to establish national agreement on medical and physiotherapy assessments, and standards of care for patients with Spinal Muscular Atrophy.

Information will be shared pseudo-anonymously with members of the NHS England SMA Clinical Panel, NICE, NHS England and the appropriate pharmaceutical company – Roche. Pseudonymised means replacing characteristics of personal data with a pseudonym, a unique value that does not allow the person to be directly identified without the use of additional information.